U.S. markets close in 3 hours
  • S&P 500

    3,778.10
    -17.44 (-0.46%)
     
  • Dow 30

    30,895.83
    -95.69 (-0.31%)
     
  • Nasdaq

    13,049.61
    -63.03 (-0.48%)
     
  • Russell 2000

    2,126.62
    -28.73 (-1.33%)
     
  • Crude Oil

    52.24
    -1.33 (-2.48%)
     
  • Gold

    1,831.10
    -20.30 (-1.10%)
     
  • Silver

    24.81
    -0.99 (-3.84%)
     
  • EUR/USD

    1.2096
    -0.0059 (-0.48%)
     
  • 10-Yr Bond

    1.0940
    -0.0350 (-3.10%)
     
  • GBP/USD

    1.3603
    -0.0088 (-0.65%)
     
  • USD/JPY

    103.8100
    -0.0060 (-0.01%)
     
  • BTC-USD

    35,840.48
    -1,998.17 (-5.28%)
     
  • CMC Crypto 200

    686.13
    -49.01 (-6.67%)
     
  • FTSE 100

    6,735.71
    -66.25 (-0.97%)
     
  • Nikkei 225

    28,519.18
    -179.08 (-0.62%)
     

Cytrx cancer drug shows promise in mid-stage study

Jan 6 (Reuters) - Cytrx Corp said interim data showed its experimental cancer drug was effective in a mid-stage study to treat patients with a deadly form of brain cancer.

The drug, aldoxorubicin, prevented the disease from progressing and shrank tumors, the company said.

The U.S. Food and Drug Administration had placed a hold on enrolling new patients in clinical trials of aldoxorubicin in November, after a patient died.

(Reporting by Rosmi Shaji in Bengaluru; Editing by Savio D'Souza)